Japan Bans CBN Effective June 2026 Under Revised Cannabis Law
Ministry of Health and Welfare designates cannabinol a controlled substance six months after medical cannabis legalization.
Urban scene of modern skyscrapers and historic Tokyo Station in vibrant morning light.
Ministry Order Adds CBN to Controlled-Substance Schedule
The Ministry of Health, Labour and Welfare designated cannabinol a controlled substance under Article 4 of the Cannabis Control Act, effective June 1, 2026. The order, published in the Official Gazette on May 30, amends the ministerial ordinance listing prohibited cannabis-derived compounds. CBN now sits alongside delta-9-THC, delta-8-THC, THCP, and HHC on the schedule.
Officials cited CBN's psychoactive properties and lack of approved medical applications in Japan. Only cannabinoids explicitly approved by the Pharmaceuticals and Medical Devices Agency (PMDA) may be manufactured, imported, or sold under the revised Cannabis Control Act. No CBN-based drug has received PMDA approval.
Possession of CBN products after June 1 carries penalties of up to five years imprisonment under Article 24-3 of the Act. Manufacturing or import violations? Up to seven years under Article 24.
Ban Follows December 2023 Medical Cannabis Legalization
Japan legalized medical cannabis in December 2023 through a comprehensive revision of the 1948 Cannabis Control Act. The same revision expanded the list of prohibited cannabinoids. The changes, effective December 12, 2023, ended a 75-year blanket ban on all cannabis-derived medicines while creating a dual-track system: PMDA-approved cannabinoid drugs are legal for prescription use, but unapproved cannabinoids face stricter enforcement.
The ministry's approach separates evidence-based medicine from unregulated cannabinoid commerce, a model distinct from North American harm-reduction frameworks.
Two cannabinoid drugs have won PMDA approval under the new framework. Epidiolex (cannabidiol oral solution) got the green light for pediatric epilepsy in March 2024. Sativex (THC/CBD oromucosal spray) followed in November 2024 for multiple sclerosis spasticity. Both approvals required full clinical trials conducted in Japanese patient populations.
For full background on Japan's medical cannabis framework, see the CannIntel topic hub on Japan Cannabis Policy.
CBN Market Impact and Enforcement Timeline
The ban targets a small but growing market for CBN sleep aids sold online and in specialty wellness shops. Most products are imported from the United States and European Union. Japan's Consumer Affairs Agency estimated the domestic CBN market at ¥2.3 billion ($15.8 million USD) in 2025, concentrated in Tokyo, Osaka, and Fukuoka metro areas. Most products are marketed as sleep supplements containing 5-25 mg CBN per dose.
Retailers have until May 31 to clear inventory. Officials haven't announced a grace period for consumer possession, meaning individuals holding CBN products after June 1 face prosecution risk. Customs enforcement begins June 1 at all ports of entry.
Police arrested 127 people for delta-8-THC possession in 2024, the first full year after that cannabinoid was banned in December 2023. CBN enforcement is expected to follow a similar pattern. Authorities will target retail distribution before individual consumers.
For complete background, history, and our ongoing coverage of this story:
Open the CannIntel topic hub →Frequently asked questions
Why is Japan banning CBN?
The Ministry of Health, Labour and Welfare cited CBN's psychoactive properties and lack of approved medical applications in Japan. Under the revised Cannabis Control Act, only cannabinoids with Pharmaceuticals and Medical Devices Agency approval may be sold. No CBN drug has received PMDA approval.
What are the penalties for CBN possession in Japan after June 1?
Possession carries up to five years imprisonment under Article 24-3 of the Cannabis Control Act. Manufacturing or import violations face up to seven years under Article 24. The law doesn't distinguish personal-use quantities from commercial amounts.
Are any cannabinoids legal in Japan?
Yes. CBD and PMDA-approved cannabinoid drugs are legal. Epidiolex (CBD oral solution) was approved in March 2024 for pediatric epilepsy. Sativex (THC/CBD spray) was approved in November 2024 for MS spasticity. Both require prescription and are dispensed through registered pharmacies.
How does Japan's cannabinoid policy differ from other countries?
Japan uses a positive-list model: only explicitly approved cannabinoids are legal. Most Western countries use negative-list models, banning specific compounds while allowing others by default. Japan's approach reflects its zero-tolerance drug policy and emphasis on pharmaceutical-grade regulation.
What happens to CBN products already purchased by consumers?
The ministry hasn't announced a grace period. Possession of any amount after June 1 is prosecutable. Consumers are advised to dispose of CBN products before the effective date. No buyback or amnesty program has been announced.
Sources
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.
Related from Laws
Tennessee Finalizes THCA and Hemp Product Ban Starting July 1
New state rules prohibit retail sale of intoxicating hemp cannabinoids including THCA, delta-8, and delta-10 effective this summer.
ADA Medical Marijuana Protections Remain Unsettled in 2026 Courts
Federal appeals courts continue splitting on whether the Americans with Disabilities Act shields medical cannabis patients from termination.
Three States File Petition to Reverse Trump Medical Cannabis Rule
California, New York, and Illinois challenge DEA's medical-only Schedule III order in federal court.
More from the newsroom
Hemp Bioplastic Outperforms PET in Packaging Study, Opening Commercial Path
New research shows hemp-derived plastic matches petroleum-based materials on durability while offering biodegradability advantages.
Colorado Cannabis Operators Face Gray-Market Squeeze as Consolidation Accelerates
Equity analysts flag margin compression and M&A activity as licensed operators compete with unregulated hemp-derived THC products flooding retail channels.
Physicians Face Growing Pressure to Learn Cannabis Medicine
Medical schools still skip endocannabinoid training as patient demand accelerates across 38 legal states.